

Supplementary Documents [IFRS]

Financial results for the first nine months of the fiscal year 2021 (FY2021)

Astellas Pharma Inc.

- Q3/FY2021 Financial Results
 - Nine months ended December 31, 2021
 - Three months ended December 31, 2021
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[Nine months ended December 31, 2021]

1. Consolidated Results (Full Basis)

	Unit: B¥				FY20 Full Year	Forecasts	
	FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)		FY21 Full Year	Change from FY20 (%)
Revenue	940.9	992.3	51.4	5.5%	1,249.5	1,323.0	5.9%
Cost of sales	187.7	194.1	6.4	3.4%	246.1		
Ratio to Revenue	20.0%	19.6%			19.7%		
Gross profit	753.2	798.2	45.0	6.0%	1,003.5		
SG&A expenses	363.0	406.4	43.4	11.9%	504.3	541.0	7.3%
Ratio to Revenue	38.6%	41.0%			40.4%	40.9%	
XTANDI co-promotion fee in the United states	90.2	108.7	18.5	20.5%	120.2		
Personnel expenses	133.9	143.0	9.2	6.9%	182.2		
Advertising and Sales Promotion and Other	139.0	154.7	15.7	11.3%	201.9		
R&D expenses	168.8	177.6	8.8	5.2%	224.5	242.0	7.8%
Ratio to Revenue	17.9%	17.9%			18.0%	18.3%	
Amortisation of intangible assets	17.3	20.2	3.0	17.1%	23.8		
Gain on divestiture of intangible assets	-	24.1	24.1	-	-		
Share of profit (loss) of investments accounted for using equity method	-0.3	2.0	2.3	-	0.5		
Other income	7.0	4.2	-2.8	-40.3%	7.6		
Net foreign exchange gains	-	0.6	0.6	-	-		
Fair value remeasurements on contingent consideration	3.9	2.2	-1.6	-42.7%	3.6		
Other expense	51.3	54.9	3.6	6.9%	123.0		
Impairment losses	36.7	26.7	-9.9	-27.1%	101.7		
Restructuring costs	2.9	18.3	15.4	542.0%	9.3		
Net foreign exchange losses	4.2	-	-4.2	-100.0%	2.3		
Fair value remeasurements on contingent consideration	4.4	8.7	4.3	97.8%	6.0		
Operating profit	159.5	169.4	9.9	6.2%	136.1	218.0	60.2%
Ratio to Revenue	16.9%	17.1%			10.9%	16.5%	
Finance income	6.5	2.3	-4.2	-64.5%	11.6		
Finance expenses	1.7	4.3	2.5	144.8%	2.3		
Profit before tax	164.2	167.4	3.2	1.9%	145.3	216.0	48.6%
Ratio to Revenue	17.5%	16.9%			11.6%	16.3%	
Income tax expense	31.3	34.9	3.6	11.5%	24.7		
Profit	132.9	132.5	-0.4	-0.3%	120.6	174.0	44.3%
Ratio to Revenue	14.1%	13.4%			9.7%	13.1%	
Comprehensive income	155.9	164.5	8.6	5.5%	181.5		

2. Consolidated Results (Core Basis)

Unit: B¥

	FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
Revenue	940.9	992.3	51.4	5.5%
Cost of sales	187.7	194.1	6.4	3.4%
Ratio to Revenue	20.0%	19.6%		
Gross profit	753.2	798.2	45.0	6.0%
SG&A expenses	363.0	406.4	43.4	11.9%
Ratio to Revenue	38.6%	41.0%		
XTANDI co-promotion fee in the United states	90.2	108.7	18.5	20.5%
Personnel expenses	133.9	143.0	9.2	6.9%
Advertising and Sales Promotion and Other	139.0	154.7	15.7	11.3%
R&D expenses	168.8	177.6	8.8	5.2%
Ratio to Revenue	17.9%	17.9%		
Amortisation of intangible assets	17.3	20.2	3.0	17.1%
Gain on divestiture of intangible assets	-	24.1	24.1	-
Share of profit (loss) of investments accounted for using equity method	-0.3	2.0	2.3	-
Operating profit	203.7	220.0	16.3	8.0%
Ratio to Revenue	21.7%	22.2%		
Finance income	6.5	2.3	-4.2	-64.5%
Finance expenses	1.7	4.3	2.5	144.8%
Profit before tax	208.5	218.1	9.6	4.6%
Ratio to Revenue	22.2%	22.0%		
Income tax expense	41.9	48.4	6.5	15.6%
Profit	166.6	169.7	3.0	1.8%
Ratio to Revenue	17.7%	17.1%		

	FY20 Full Year	Forecasts FY21 Full Year	Change from FY20 (%)
Revenue	1,249.5	1,323.0	5.9%
Cost of sales	246.1		
Ratio to Revenue	19.7%		
Gross profit	1,003.5		
SG&A expenses	504.3	541.0	7.3%
Ratio to Revenue	40.4%	40.9%	
XTANDI co-promotion fee in the United states	120.2		
Personnel expenses	182.2		
Advertising and Sales Promotion and Other	201.9		
R&D expenses	224.5	242.0	7.8%
Ratio to Revenue	18.0%	18.3%	
Amortisation of intangible assets	23.8		
Gain on divestiture of intangible assets	-		
Share of profit (loss) of investments accounted for using equity method	0.5		
Operating profit	251.4	270.0	7.4%
Ratio to Revenue	20.1%	20.4%	
Finance income	11.6		
Finance expenses	2.3		
Profit before tax	260.6		
Ratio to Revenue	20.9%		
Income tax expense	50.7		
Profit	209.9	213.0	1.5%
Ratio to Revenue	16.8%	16.1%	

3. Exchange Rate

Unit: yen

	FY20 APR. - DEC.Ave.	FY21 APR. - DEC.Ave.	FY20 End	FY21 Q3 End
USD/Yen	106	111	111	115
EUR/Yen	122	131	130	131

	FY20 Full Year	Forecasts FY21 Full Year
USD/Yen	106	110
EUR/Yen	124	130

* Fx impacts: Revenue +42.8 billion yen and Core operating profit +15.4 billion yen

* Fx impact on elimination of unrealized gain: COGs ratio +0.2ppt

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY20 APR. - DEC.			FY21 APR. - DEC.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	940.9	-	940.9	992.3	-	992.3
Cost of sales	187.7	-	187.7	194.1	-	194.1
Gross profit	753.2	-	753.2	798.2	-	798.2
SG&A expenses	363.0	-	363.0	406.4	-	406.4
R&D expenses	168.8	-	168.8	177.6	-	177.6
Amortisation of intangible assets	17.3	-	17.3	20.2	-	20.2
Gain on divestiture of intangible assets	-	-	-	24.1	-	24.1
Share of profit (loss) of investments accounted for using equity method	-0.3	-	-0.3	2.0	-	2.0
Other income *	7.0	-7.0	-	4.2	-4.2	-
Other expenses *	51.3	-51.3	-	54.9	-54.9	-
Operating profit	159.5	44.3	203.7	169.4	50.7	220.0
Finance income	6.5	-	6.5	2.3	-	2.3
Finance expenses	1.7	-	1.7	4.3	-	4.3
Profit before tax	164.2	44.3	208.5	167.4	50.7	218.1
Income tax expense	31.3	10.6	41.9	34.9	13.5	48.4
Profit	132.9	33.7	166.6	132.5	37.2	169.7

* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

		Unit: B¥			
		FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
Revenue		940.9	992.3	51.4	5.5%
	Japan	221.8	203.2	-18.6	-8.4%
	Ratio to Revenue	23.6%	20.5%		
	United States	355.8	407.9	52.1	14.7%
	Ratio to Revenue	37.8%	41.1%		
	Established Markets	218.0	239.2	21.3	9.8%
	Ratio to Revenue	23.2%	24.1%		
	Greater China	43.8	50.3	6.5	14.8%
	Ratio to Revenue	4.7%	5.1%		
	International Markets	87.6	83.0	-4.6	-5.3%
	Ratio to Revenue	9.3%	8.4%		
	Others	13.9	8.6	-5.3	-38.0%
	Ratio to Revenue	1.5%	0.9%		

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

		Change from FY20	
		Forecasts FY21 Full Year	Change (%)
	FY20 Full Year	1,249.5	
	FY21 Full Year	1,323.0	5.9%
	Japan	279.1	-9.7%
	Ratio to Revenue	22.3%	
	United States	473.2	16.8%
	Ratio to Revenue	37.9%	
	Established Markets	293.2	9.9%
	Ratio to Revenue	23.5%	
	Greater China	59.3	9.6%
	Ratio to Revenue	4.7%	
	International Markets	111.1	10.2%
	Ratio to Revenue	8.9%	
	Others	33.6	-73.5%
	Ratio to Revenue	2.7%	

6. Addition to Property, Plant and Equipment
Depreciation/Amortisation

		Unit: B¥			
		FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
Addition to Property, Plant and Equipment					
	Consolidated	23.9	22.3	-1.5	-6.4%
Depreciation (PP&E)					
	Consolidated	30.1	30.3	0.3	0.9%
Amortisation of Intangible Assets (incl. software, etc.)					
	Consolidated	24.0	28.3	4.2	17.6%

- Addition to Property, Plant and Equipment does not include right-of-use asset

		Change from FY20	
		Forecasts FY21 Full Year	Change (%)
	FY20 Full Year		
	FY21 Full Year	34.0	0.9%
	Depreciation (PP&E)	42.0	5.0%
	Amortisation of Intangible Assets (incl. software, etc.)	38.0	16.3%

7. Sales of major products

1) Global

		Unit: B¥				Forecasts		Change from FY20	
		FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)	FY20 Full Year	FY21 Full Year	Change (%)	
XTANDI		342.7	411.6	68.9	20.1%	458.4	554.1	20.9%	
	United States	180.0	215.8	35.7	19.8%	238.6	290.2	21.6%	
	ex-US	162.7	195.8	33.1	20.4%	219.8	264.0	20.1%	
	Japan	31.0	36.5	5.5	17.6%	40.2	47.1	17.2%	
	Established Markets	108.8	128.8	20.0	18.4%	149.3	176.0	17.9%	
	Greater China	3.2	5.5	2.3	70.6%	4.9	8.2	68.2%	
	International Markets	19.6	25.0	5.4	27.4%	25.5	32.6	28.0%	
XOSPATA		17.6	25.7	8.1	45.8%	23.8	35.4	48.3%	
	Japan	2.9	3.1	0.2	6.5%	3.8	4.4	15.9%	
	United States	11.6	14.4	2.8	24.7%	15.5	19.2	24.1%	
	Established Markets	3.1	6.5	3.4	107.1%	4.4	9.4	114.8%	
	Greater China	0.0	1.3	1.3	-	0.0	1.7	-	
	International Markets	0.0	0.4	0.3	716.7%	0.2	0.6	315.8%	
PADCEV		9.4	14.6	5.2	55.7%	12.8	20.7	61.4%	
	Japan	-	0.5	0.5	-	-	0.8	-	
	United States	9.4	14.0	4.6	49.5%	12.8	19.7	53.4%	
	Established Markets	-	0.0	0.0	-	-	0.2	-	
EVRENZO		0.7	2.1	1.4	198.6%	1.1	7.2	540.8%	
	Japan	0.7	2.0	1.3	181.2%	1.1	4.1	262.8%	
	Established Markets	-	0.1	0.1	-	-	3.2	-	
Betanis/Myrabetriq/BETMIGA		122.3	126.9	4.6	3.8%	163.6	176.3	7.8%	
	Japan	26.6	29.2	2.6	9.6%	35.1	36.7	4.5%	
	United States	65.9	61.9	-4.0	-6.1%	88.0	93.0	5.7%	
	Established Markets	21.9	27.6	5.7	25.9%	29.9	35.7	19.7%	
	Greater China	1.6	2.0	0.5	29.2%	2.2	2.7	23.1%	
	International Markets	6.3	6.2	-0.1	-1.1%	8.5	8.2	-3.6%	
Vesicare		24.7	17.9	-6.7	-27.3%	31.6	18.9	-40.3%	
	Japan	14.5	8.6	-5.9	-40.7%	18.5	7.6	-59.0%	
	United States	1.9	1.4	-0.5	-26.4%	2.2	1.5	-33.2%	
	Established Markets	4.6	4.2	-0.4	-9.2%	6.2	5.2	-17.1%	
	Greater China	0.8	0.8	0.0	3.1%	1.0	1.0	1.5%	
	International Markets	2.8	2.9	0.1	3.7%	3.7	3.6	-2.4%	
Prograf		138.3	141.1	2.8	2.0%	182.7	185.7	1.7%	
	Japan	32.1	30.3	-1.8	-5.6%	40.7	38.2	-6.3%	
	United States	9.4	7.6	-1.8	-19.7%	11.8	9.1	-23.1%	
	Established Markets	47.6	51.9	4.3	9.1%	64.2	67.3	5.0%	
	Greater China	24.8	29.8	5.0	20.2%	34.2	37.9	10.8%	
	International Markets	24.4	21.5	-2.9	-11.8%	31.7	33.2	4.8%	
Eligard		9.3	-	-9.3	-	9.5	-	-	

- Sales of products in Japan are shown in a gross sales basis

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
XTANDI	31.0	36.5	5.5	17.6%
XOSPATA	2.9	3.1	0.2	6.5%
PADCEV	-	0.5	0.5	-
EVRENZO	0.7	2.0	1.3	181.2%
Betanis	26.6	29.2	2.6	9.6%
Vesicare	14.5	8.6	-5.9	-40.7%
Prograf (Including Graceptor)	32.1	30.3	-1.8	-5.6%
Harnal	2.4	2.0	-0.4	-15.4%
Funguard	4.0	1.4	-2.7	-66.2%

FY20 Full Year
40.2
3.8
-
1.1
35.1
18.5
40.7
3.0
4.4

Forecasts		Change from FY20
FY21 Full Year	Change (%)	
47.1	17.2%	
4.4	15.9%	
0.8	-	
4.1	262.8%	
36.7	4.5%	
7.6	-59.0%	
38.2	-6.3%	
2.4	-19.9%	
1.5	-65.3%	

<Main products>

Suglat [Family]	21.6	23.7	2.1	9.8%
Sujanu	8.7	9.7	1.0	11.5%
Repatha	3.9	4.5	0.6	14.3%
Linzess	4.9	5.4	0.5	10.7%
BLINCYTO	3.4	4.7	1.3	39.5%
EVENTY	19.0	23.3	4.3	22.4%
Smyraf	1.1	1.9	0.7	63.6%
Celecox	16.9	-	-16.9	-
Geninax	2.0	2.1	0.1	4.6%
Vaccines	7.9	5.2	-2.7	-34.0%
Gonax	4.0	3.9	-0.1	-1.4%
Cimzia	7.7	8.7	1.0	12.8%
Lipitor	8.4	-	-8.4	-
Myslee	6.2	5.5	-0.7	-10.6%
Total Rx Sales In Japanese market	219.6	201.7	-17.9	-8.2%

27.9
11.3
5.1
6.4
4.5
24.8
1.7
18.9
2.5
7.9
5.1
10.0
10.6
7.8
276.6

30.5	9.4%
7.0	9.4%
3.1	89.3%
3.1	24.2%
5.2	-34.6%
5.0	-1.7%
6.9	-12.3%
250.3	-9.5%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M\$

	FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
Revenue	3,353	3,672	319	9.5%
XTANDI	1,697	1,942	245	14.5%
XOSPATA	109	130	21	19.1%
PADCEV	88	126	38	42.8%
Myrbetriq	621	557	-64	-10.3%
Vesicare	18	13	-5	-29.7%
Prograf	89	68	-21	-23.3%
MYCAMINE	63	41	-22	-34.7%
AmBisome	85	101	16	18.6%
CRESEMBA	120	143	22	18.6%
Lexiscan	456	551	95	20.8%

FY20 Full Year
4,462
2,250
146
121
829
20
112
83
114
160
623

Forecasts		Change from FY20
FY21 Full Year	Change (%)	
5,022	12.6%	
2,638	17.3%	
175	19.6%	
179	47.9%	
845	1.9%	
13	-35.6%	
83	-25.8%	
45	-45.3%	
127	12.3%	
185	16.0%	
732	17.5%	

(3) Established Markets

Unit: M€

	FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
Revenue	1,781	1,832	51	2.9%
XTANDI	889	986	98	11.0%
XOSPATA	26	50	24	94.1%
PADCEV	-	0	0	-
EVRENZO	-	1	1	-
BETMIGA	179	212	32	18.0%
Vesicare	38	32	-6	-14.9%
Prograf	389	397	9	2.2%
Omnice	49	51	2	4.4%
MYCAMINE	36	18	-18	-49.9%
Eligard	64	-	-64	-

FY20 Full Year
2,370
1,207
36
-
-
241
50
519
65
45
64

FY21 Full Year	Change (%)
2,477	4.5%
1,354	12.2%
73	104.4%
1	-
24	-
275	13.9%
40	-21.1%
518	-0.1%
65	0.0%
23	-48.0%
-	-

- Established Markets: Europe, Canada, Australia

(4) Greater China

	Unit: B¥			
	FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
Revenue	43.8	50.3	6.5	14.8%
XTANDI	3.2	5.5	2.3	70.6%
XOSPATA	0.0	1.3	1.3	-
BETMIGA	1.6	2.0	0.5	29.2%
Vesicare	0.8	0.8	0.0	3.1%
Prograf	24.8	29.8	5.0	20.2%
Harnal	8.9	6.1	-2.8	-31.6%
MYCAMINE	1.8	2.1	0.3	17.2%
Feburic	1.9	2.1	0.1	7.6%

- Greater China: China, Hong Kong, Taiwan

	Change from FY20	
	Forecasts FY21 Full Year	Change (%)
FY20 Full Year	59.3	
	65.0	9.6%
	4.9	8.2
	8.2	68.2%
	0.0	1.7
	1.7	-
	2.2	2.7
	2.7	23.1%
	1.0	1.0
	1.0	1.5%
	34.2	37.9
	37.9	10.8%
	10.8	7.9
	7.9	-27.5%
	2.5	2.2
	2.2	-13.0%
	2.6	2.7
	2.7	1.9%

(5) International Markets

	Unit: B¥			
	FY20 APR. - DEC.	FY21 APR. - DEC.	Change	Change (%)
Revenue	87.6	83.0	-4.6	-5.3%
XTANDI	19.6	25.0	5.4	27.4%
XOSPATA	0.0	0.4	0.3	716.7%
BETMIGA	6.3	6.2	-0.1	-1.1%
Vesicare	2.8	2.9	0.1	3.7%
Prograf	24.4	21.5	-2.9	-11.8%
Harnal	11.6	12.7	1.1	9.1%
MYCAMINE	3.1	4.7	1.6	49.8%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

	Change from FY20	
	Forecasts FY21 Full Year	Change (%)
FY20 Full Year	111.1	
	122.5	10.2%
	25.5	32.6
	0.2	0.6
	0.2	315.8%
	8.5	8.2
	8.2	-3.6%
	3.7	3.6
	3.7	-2.4%
	31.7	33.2
	33.2	4.8%
	15.1	16.2
	15.1	7.2%
	4.4	6.1
	4.4	40.2%

8. Consolidated statements of financial position

Unit: B¥

	FY20 End	FY21 Q3 End	Change
Assets	2,273.6	2,356.2	82.6
Non-current assets	1,401.0	1,416.9	15.9
Property, plant and equipment	264.6	267.8	3.2
Goodwill	284.0	293.6	9.6
Intangible assets	651.4	652.3	0.8
Trade and other receivables	33.9	30.4	-3.6
Investments accounted for using equity method	7.1	10.9	3.8
Deferred tax assets	54.2	58.5	4.3
Other financial assets	95.9	93.4	-2.4
Other non-current assets	9.9	10.1	0.2
Current assets	872.6	939.3	66.7
Inventories	164.1	151.6	-12.5
Trade and other receivables	343.2	373.9	30.7
Income tax receivable	14.0	16.8	2.8
Other financial assets	5.6	17.9	12.3
Other current assets	19.7	28.9	9.3
Cash and cash equivalents	326.1	350.2	24.1

Unit: B¥

	FY20 End	FY21 Q3 End	Change
Equity and Liabilities	2,273.6	2,356.2	82.6
Equity	1,386.1	1,466.3	80.2
Equity attributable to owners of the parent	1,386.1	1,466.3	80.2
Share capital	103.0	103.0	-
Capital surplus	177.8	179.0	1.2
Treasury shares	-15.4	-15.5	-0.1
Retained earnings	953.3	999.6	46.4
Other components of equity	167.4	200.1	32.8
Liabilities	887.5	890.0	2.4
Non-current liabilities	295.1	292.0	-3.2
Trade and other payables	0.4	0.7	0.3
Deferred tax liabilities	18.2	10.6	-7.5
Retirement benefit liabilities	39.0	37.9	-1.0
Provisions	5.8	4.3	-1.5
Other financial liabilities	199.0	201.5	2.5
Other non-current liabilities	32.8	36.9	4.1
Current liabilities	592.4	598.0	5.6
Trade and other payables	124.8	136.9	12.1
Income tax payable	8.4	22.0	13.6
Provisions	22.2	14.0	-8.2
Other financial liabilities	148.2	108.7	-39.5
Other current liabilities	288.9	316.4	27.6

[Three months ended December 31, 2021]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY21					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	326.1	6.2%	325.5	5.5%	340.6	4.7%
Cost of sales	62.2	4.3%	62.5	4.4%	69.4	1.7%
Ratio to Revenue	19.1%		19.2%		20.4%	
Gross profit	263.9	6.7%	263.0	5.8%	271.3	5.5%
SG&A expenses	137.1	13.5%	133.4	9.9%	135.9	12.4%
Ratio to Revenue	42.0%		41.0%		39.9%	
XTANDI co-promotion fee in the United states	34.5	9.4%	36.6	24.8%	37.6	28.0%
Personnel expenses	49.0	7.3%	47.0	5.5%	47.0	7.8%
Advertising and Sales Promotion and Other	53.6	23.0%	49.8	4.9%	51.3	7.0%
R&D expenses	58.3	1.8%	60.7	11.6%	58.6	2.6%
Ratio to Revenue	17.9%		18.7%		17.2%	
Amortisation of intangible assets	6.0	1.8%	6.4	12.7%	7.9	37.0%
Gain on divestiture of intangible assets	-	-	-	-	24.1	-
Share of profit (loss) of investments accounted for using equity method	0.3	-	0.0	-	1.7	-
Other income	0.4	-82.0%	2.4	-24.6%	3.1	-20.8%
Net foreign exchange gains	0.3	-70.5%	2.0	-	-	-100.0%
Fair value remeasurements on contingent consideration	-	-	0.0	-99.9%	2.2	-
Other expense	27.1	465.2%	10.8	-75.4%	18.6	292.3%
Impairment losses	26.1	690.7%	0.0	-100.0%	0.7	-68.5%
Restructuring costs	0.6	-	2.0	116.7%	15.8	713.6%
Net foreign exchange losses	-	-	-	-100.0%	1.7	-
Fair value remeasurements on contingent consideration	0.0	91.4%	8.7	109.5%	0.0	-92.6%
Operating profit	36.1	-40.7%	54.1	107.5%	79.2	9.1%
Ratio to Revenue	11.1%		16.6%		23.3%	
Finance income	1.5	284.3%	0.4	-85.9%	0.4	-86.4%
Finance expenses	1.7	79.6%	1.3	363.6%	1.3	150.7%
Profit before tax	35.8	-40.5%	53.3	84.6%	78.3	4.2%
Ratio to Revenue	11.0%		16.4%		23.0%	
Income tax expense	5.1	-47.7%	12.3	91.9%	17.4	15.8%
Profit	30.7	-39.1%	40.9	82.5%	60.9	1.3%
Ratio to Revenue	9.4%		12.6%		17.9%	
Comprehensive income	36.2	-34.7%	33.9	49.4%	94.5	21.4%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY21					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	326.1	6.2%	325.5	5.5%	340.6	4.7%
Cost of sales	62.2	4.3%	62.5	4.4%	69.4	1.7%
Ratio to Revenue	19.1%		19.2%		20.4%	
Gross profit	263.9	6.7%	263.0	5.8%	271.3	5.5%
SG&A expenses	137.1	13.5%	133.4	9.9%	135.9	12.4%
Ratio to Revenue	42.0%		41.0%		39.9%	
XTANDI co-promotion fee in the United states	34.5	9.4%	36.6	24.8%	37.6	28.0%
Personnel expenses	49.0	7.3%	47.0	5.5%	47.0	7.8%
Advertising and Sales Promotion and Other	53.6	23.0%	49.8	4.9%	51.3	7.0%
R&D expenses	58.3	1.8%	60.7	11.6%	58.6	2.6%
Ratio to Revenue	17.9%		18.7%		17.2%	
Amortisation of intangible assets	6.0	1.8%	6.4	12.7%	7.9	37.0%
Gain on divestiture of intangible assets	-	-	-	-	24.1	-
Share of profit (loss) of investments accounted for using equity method	0.3	-	0.0	-	1.7	-
Operating profit	62.8	-0.9%	62.5	-6.6%	94.8	29.0%
Ratio to Revenue	19.3%		19.2%		27.8%	
Finance income	1.5	284.3%	0.4	-85.9%	0.4	-86.4%
Finance expenses	1.7	79.6%	1.3	363.6%	1.3	150.7%
Profit before Tax	62.6	-0.4%	61.7	-11.6%	93.9	23.5%
Ratio to Revenue	19.2%		18.9%		27.6%	
Income tax expense	13.3	23.3%	12.1	-21.9%	22.9	47.8%
Profit	49.2	-5.3%	49.5	-8.6%	70.9	17.3%
Ratio to Revenue	15.1%		15.2%		20.8%	

3. Revenue by Region

Unit: B¥

		FY21					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Revenue		326.1	6.2%	325.5	5.5%	340.6	4.7%
	Japan	67.5	-13.2%	63.0	-5.2%	72.7	-6.3%
	Ratio to Revenue	20.7%		19.4%		21.3%	
	United States	133.6	14.1%	136.5	14.1%	137.8	15.7%
	Ratio to Revenue	41.0%		41.9%		40.5%	
	Established Markets	78.0	21.8%	79.4	6.0%	81.9	3.5%
	Ratio to Revenue	23.9%		24.4%		24.0%	
	Greater China	16.4	15.5%	16.6	8.3%	17.3	21.2%
	Ratio to Revenue	5.0%		5.1%		5.1%	
	International Markets	27.8	-8.1%	27.5	3.7%	27.7	-10.3%
	Ratio to Revenue	8.5%		8.4%		8.1%	
	Others	2.8	-21.9%	2.5	-55.9%	3.3	-28.1%
	Ratio to Revenue	0.9%		0.8%		1.0%	

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

4. Addition to Property, Plant and Equipment

Unit: B¥

		FY21					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Addition to Property, Plant and Equipment							
	Consolidated	5.2	-27.3%	7.8	4.9%	9.3	0.3%
Depreciation (PP&E)							
	Consolidated	9.9	-0.6%	10.0	-0.1%	10.4	3.5%
Amortisation of Intangible Assets (incl. software, etc.)							
	Consolidated	8.2	2.6%	9.0	12.7%	11.1	37.4%

- Addition to Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY21					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI		132.9	18.7%	134.7	18.6%	143.9	22.8%
	United States	68.4	9.1%	72.7	24.5%	74.6	26.6%
	ex-US	64.5	31.0%	62.0	12.4%	69.3	18.9%
	Japan	12.0	18.5%	11.5	17.9%	12.9	16.6%
	Established Markets	42.8	36.1%	41.1	9.9%	44.9	12.4%
	Greater China	1.9	165.1%	1.7	11.1%	1.9	97.9%
	International Markets	7.8	12.2%	7.6	18.8%	9.6	52.9%
XOSPATA		8.3	47.7%	8.2	53.0%	9.2	38.4%
	Japan	1.1	6.6%	1.0	19.0%	1.0	-3.5%
	United States	4.6	26.9%	4.4	21.1%	5.4	25.8%
	Established Markets	2.0	99.4%	2.1	156.3%	2.4	81.8%
	Greater China	0.5	-	0.5	-	0.3	-
	International Markets	0.1	-	0.1	785.7%	0.1	321.1%
PADCEV		4.2	41.9%	4.9	60.8%	5.5	63.2%
	Japan	-	-	-	-	0.5	-
	United States	4.2	41.9%	4.9	60.8%	4.9	45.9%
	Established Markets	-	-	-	-	0.0	-
EVRENZO		0.6	282.9%	0.8	352.1%	0.7	91.3%
	Japan	0.6	282.9%	0.7	288.3%	0.7	88.2%
	Established Markets	-	-	0.1	-	0.0	-
Betanis/Myrabetriq/BETMIGA		44.0	8.8%	40.4	2.2%	42.5	0.5%
	Japan	9.8	16.2%	8.9	8.5%	10.5	4.8%
	United States	22.8	-0.5%	19.3	-8.9%	19.9	-9.1%
	Established Markets	8.5	29.4%	9.4	21.0%	9.7	27.9%
	Greater China	0.7	56.9%	0.6	23.5%	0.7	15.0%
	International Markets	2.2	5.8%	2.3	15.3%	1.8	-21.7%
Vesicare		7.4	-4.4%	5.4	-36.6%	5.2	-38.8%
	Japan	4.6	-7.7%	2.0	-55.3%	2.1	-59.9%
	United States	0.2	-39.4%	0.7	-46.3%	0.5	67.6%
	Established Markets	1.4	14.4%	1.5	-6.6%	1.2	-29.0%
	Greater China	0.3	22.3%	0.2	-10.2%	0.3	-0.4%
	International Markets	0.9	-3.9%	1.0	6.0%	1.1	8.4%
Prograf		45.2	-0.3%	47.1	6.4%	48.8	0.2%
	Japan	10.2	-7.9%	9.4	-5.3%	10.7	-3.5%
	United States	2.1	-40.8%	2.7	-11.7%	2.8	-1.7%
	Established Markets	16.2	17.0%	18.2	9.9%	17.5	1.8%
	Greater China	9.6	22.9%	9.9	17.7%	10.3	20.1%
	International Markets	7.0	-21.7%	6.9	8.9%	7.6	-16.4%

- Sales of products in Japan are shown in a gross sales basis

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	FY21					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
XTANDI	12.0	18.5%	11.5	17.9%	12.9	16.6%
XOSPATA	1.1	6.6%	1.0	19.0%	1.0	-3.5%
PADCEV	-	-	-	-	0.5	-
EVRENZO	0.6	282.9%	0.7	288.3%	0.7	88.2%
Betanis	9.8	16.2%	8.9	8.5%	10.5	4.8%
Vesicare	4.6	-7.7%	2.0	-55.3%	2.1	-59.9%
Prograf (Including Graceptor)	10.2	-7.9%	9.4	-5.3%	10.7	-3.5%
Harnal	0.7	-20.2%	0.6	-15.1%	0.7	-10.6%
Funguard	0.4	-70.7%	0.4	-68.3%	0.5	-58.0%

<Main products>

Suglat [Family]	7.9	10.9%	7.5	11.8%	8.3	7.1%
Sujanu	3.2	13.6%	3.1	15.2%	3.4	6.5%
Repatha	1.5	25.3%	1.4	9.8%	1.6	9.5%
Linzess	1.8	12.9%	1.7	11.7%	2.0	7.9%
BLINCYTO	1.4	17.6%	1.5	52.2%	1.8	50.0%
EVENITY	7.0	1.6%	7.4	28.8%	8.8	39.2%
Smyraf	0.6	179.6%	0.6	52.3%	0.7	22.2%
Geninax	0.7	15.4%	0.6	19.3%	0.8	-11.1%
Vaccines	0.0	0.0%	2.0	-29.0%	3.2	-36.5%
Gonax	1.3	-20.3%	1.3	3.4%	1.3	20.8%
Cimzia	2.8	12.3%	2.8	14.1%	3.1	12.1%
Myslee	1.8	-11.4%	1.8	-10.7%	1.9	-9.9%
Total Rx Sales In Japanese market	67.0	-12.9%	62.6	-5.3%	72.0	-5.9%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M\$

		FY21					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		1,221	12.1%	1,240	10.2%	1,211	6.3%
	XTANDI	625	7.2%	661	20.1%	656	16.4%
	XOSPATA	42	24.7%	40	16.9%	48	16.3%
	PADCEV	38	39.5%	45	55.3%	43	34.4%
	Myrbetriq	208	-2.2%	175	-12.2%	174	-16.7%
	Vesicare	2	-40.4%	6	-47.9%	5	50.9%
	Prograf	19	-41.8%	24	-14.9%	25	-9.6%
	MYCAMINE	14	-40.4%	16	-25.8%	11	-38.3%
	Ambisome	30	35.9%	38	29.3%	33	-2.3%
	CRESEMBA	45	25.8%	49	23.5%	48	8.4%
	Lexiscan	196	77.1%	186	3.1%	169	2.3%

(3) Established Markets

Unit: M€

		FY21					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		591	9.4%	612	1.2%	629	-1.1%
	XTANDI	325	22.2%	317	4.9%	345	7.4%
	XOSPATA	15	79.0%	16	146.7%	18	73.2%
	PADCEV	-	-	-	-	0	-
	EVRENZO	-	-	1	-	0	-
	BETMIGA	65	16.2%	72	15.4%	75	22.4%
	Vesicare	11	2.7%	12	-11.1%	9	-32.1%
	Prograf	123	5.1%	140	4.8%	134	-2.7%
	Omnice	17	12.2%	19	12.1%	16	-9.6%
	MYCAMINE	7	-47.6%	6	-47.7%	5	-54.9%

- Established Markets: Europe, Canada, Australia

(4) Greater China

Unit: B¥

		FY21					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		16.4	15.5%	16.6	8.3%	17.3	21.2%
	XTANDI	1.9	165.1%	1.7	11.1%	1.9	97.9%
	XOSPATA	0.5	-	0.5	-	0.3	-
	BETMIGA	0.7	56.9%	0.6	23.5%	0.7	15.0%
	Vesicare	0.3	22.3%	0.2	-10.2%	0.3	-0.4%
	Prograf	9.6	22.9%	9.9	17.7%	10.3	20.1%
	Harnal	2.0	-46.8%	2.0	-33.4%	2.1	-3.6%
	MYCAMINE	0.6	25.3%	0.7	1.7%	0.8	28.2%
	Feburic	0.6	9.7%	0.7	15.0%	0.7	-0.4%

- Greater China: China, Hong Kong, Taiwan

(5) International Markets

Unit: B¥

		FY21					
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue		27.8	-8.1%	27.5	3.7%	27.7	-10.3%
	XTANDI	7.8	12.2%	7.6	18.8%	9.6	52.9%
	XOSPATA	0.1	-	0.1	785.7%	0.1	321.1%
	BETMIGA	2.2	5.8%	2.3	15.3%	1.8	-21.7%
	Vesicare	0.9	-3.9%	1.0	6.0%	1.1	8.4%
	Prograf	7.0	-21.7%	6.9	8.9%	7.6	-16.4%
	Harnal	4.3	2.1%	3.8	-2.4%	4.6	30.4%
	MYCAMINE	1.6	64.6%	2.0	97.2%	1.1	-5.0%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Feb 2022

Underlined items indicate changes from the previous announcement in Oct 2021.

XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China P-III	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	P-III		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	<u>P-I</u>		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Acute myeloid leukemia in pediatric patients	P-III		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, PD-1/PD-L1 inhibitor and platinum-containing chemotherapy pretreated	Europe Filed (Mar 2021)	In-house [Co-development with Seagen]	
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		

XTANDI and Strategic products (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
zolibetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
roxadustat ASP1517/FG-4592 (EVRENZO)	Small molecule	HIF-PH inhibitor	Chemotherapy-induced anemia	P-II	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa
fezolinetant ESN364	Small molecule	NK3 receptor antagonist	Vasomotor symptoms associated with menopause	P-III	In-house (Ogeda)	
resamirigene bilparovect AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Oct 2021):

gilteritinib (ASP2215): Entered into Phase 1 for newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy.

enfortumab vedotin (ASG-22ME): Removed the description of the approval in Japan in Sep 2021 for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy.

roxadustat (ASP1517/FG-4592): Removed the description of the approval in Europe in Aug 2021 for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Immunology	ASP1951/PTZ-522	Antibody	G1TR agonistic antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP9801	Oncolytic virus	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	WT1 loaded artificial adjuvant vector cell	Acute myeloid leukemia and myelodysplastic syndrome	P-II	RIKEN [Discovered through collaborative research]	
				Solid tumor	P-I		
	ASP0739	Cell therapy (artificial adjuvant vector cells)	NY-ESO-1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration, Stargardt disease	P-I	In-house (Ocata Therapeutics)	
Mitochondria Biology	ASP1128/MA-0217	Small molecule	PPARδ modulator	Acute kidney injury	P-II	In-house (Mitobridge)	
	bocidelpar ASP0367/MA-0211	Small molecule	PPARδ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
				Duchenne muscular dystrophy	P-I		

Projects with Focus Area approach (2/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Genetic regulation	resamirigene bilparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
(Other projects with Focus Area approach)	ASP3772	Next generation vaccine (MAPS technology)	Pneumococcal vaccine based on a multiple antigen-presenting system (MAPS) platform	Prevention of pneumococcal disease	P-II	Affinivax	
	FX-322	Small molecule	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP0598	Recombinant protein	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	
	ASP2390	New generation vaccine (LAMP-Vax technology)		House dust mite-induced allergic rhinitis	P-I	Immunomic Therapeutics [Discovered through collaborative research]	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** AT132 is also listed in "XTANDI and Strategic products".

Updates from the previous announcement (Oct 2021):

ASP1948: Discontinued Phase 1 program for cancer.

ASP1570: Described the classification.

ASP2138: Entered into Phase 1 for gastric and gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
			Overactive bladder in pediatric patients	Europe P-III		
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China P-III	In-house	
isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
ASP8062	Small molecule	GABA _B receptor positive allosteric modulator	Opioid use disorder	P-II	In-house	
			Alcohol use disorder	P-I		

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Rx+ Program

As of Feb 2022

Underlined items indicate changes from the previous announcement in Oct 2021.

Sphere (Business area)	Program	Concept	Status *	Partner	Remarks
Chronic disease progression prevention	Game application for exercise support	Smartphone application to support exercise using motion sensing technology for people who needs regular exercise	Under development	BANDAI NAMCO Entertainment	
	Fit-eNce	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise	Launched in limited areas		
	Fit-eNce Home	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise at home	Under test marketing		
	BlueStar	Digital therapeutics for adults with diabetes	Under development	Welldoc	
Patient outcome maximization	<u>pudexacianinium ASP5354</u>	Precision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.	<u>P-III</u>		

* The list shows the most advanced stage if the stages are different depending on the region.

Updates from the previous announcement (Oct 2021):

pudexacianinium (ASP5354): Added the generic name. Entered into Phase 3.

EG Holter: Removed the description of the program which obtained certification in Aug 2021.